MedTrace Logo

Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens

NCT02749838 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2016-04-25

No results posted yet for this study

Summary

Purpose of the Protocol:

* To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents, for the purpose of selecting the most clinically appropriate anticancer therapy, including clinical trial opportunities.
* To collect and analyze biospecimens from cancer patients, using primarily standard of care laboratory methods, for the purpose of determining the expression of specific genotypic and phenotypic disease markers of scientific and medical interest.
* To create a protocol database, including case and disease stage-matched clinical and therapeutic history data in addition to patient biomarker profiles, to serve as:

* a systematic collection of data for comparing patient data to clinical trial selection criteria for the purpose of informing a clinical investigative site of available clinical trials matching patient clinical status;
* a collection of clinically matched, comprehensive molecular results for scientific and research and development applications.

Conditions

Sponsors & Collaborators

  • Paradigm

    collaborator UNKNOWN

  • Pharmatech

    lead INDUSTRY

Principal Investigators

  • Matthew B Wiener, PharmD · Pharmatech Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749838 on ClinicalTrials.gov